RT Journal Article
SR Electronic
T1 Lineage replacement and evolution captured by the United Kingdom Covid Infection Survey
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.05.21268323
DO 10.1101/2022.01.05.21268323
A1 Lythgoe, Katrina A.
A1 Golubchik, Tanya
A1 Hall, Matthew
A1 House, Thomas
A1 MacIntyre-Cockett, George
A1 Fryer, Helen
A1 Thomson, Laura
A1 Nurtay, Anel
A1 Buck, David
A1 Green, Angie
A1 Trebes, Amy
A1 Piazza, Paolo
A1 Lonie, Lorne J
A1 Studley, Ruth
A1 Rourke, Emma
A1 Cook, Duncan
A1 Smith, Darren
A1 Bashton, Matthew
A1 Nelson, Andrew
A1 Crown, Matthew
A1 McCann, Clare
A1 Young, Gregory R
A1 dos Santos, Rui Andre Nunes
A1 Richards, Zack
A1 Tariq, Adnan
A1 ,
A1 ,
A1 ,
A1 Fraser, Christophe
A1 Diamond, Ian
A1 Barrett, Jeff
A1 Walker, Sarah
A1 Bonsall, David
YR 2022
UL http://medrxiv.org/content/early/2022/01/05/2022.01.05.21268323.abstract
AB The Office for National Statistics COVID-19 Infection Survey is a large household-based surveillance study based in the United Kingdom. Here, we report on the epidemiological and evolutionary dynamics of SARS-CoV-2 determined by analysing sequenced samples collected up until 13th November 2021. We observed four distinct sweeps or partial-sweeps, by lineages B.1.177, B.1.1.7/Alpha, B.1.617.2/Delta, and finally AY.4.2, a sublineage of B.1.617.2, with each sweeping lineage having a distinct growth advantage compared to their predecessors. Evolution was characterised by steady rates of evolution and increasing diversity within lineages, but with step increases in divergence associated with each sweeping major lineage, leading to a faster overall rate of evolution and fluctuating levels of diversity. These observations highlight the value of viral sequencing integrated into community surveillance studies to monitor the viral epidemiology and evolution of SARS-CoV-2, and potentially other pathogens, particularly as routine PCR testing is phased out or in settings where large-scale sequencing is not feasible.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe CIS is funded by the Department of Health and Social Care with in-kind support from the Welsh Government, the Department of Health on behalf of the Northern Ireland Government and the Scottish Government. COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) [grant code: MC_PC_19027], and Genome Research Limited, operating as the Wellcome Sanger Institute. The authors acknowledge the support of the NHS Test and Trace Genomics Programme through sequencing of SARS-CoV-2 genomes analysed in this study. ASW is supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with the UK Health Security Agency (UK HSA) (NIHR200915) and the NIHR Oxford Biomedical Research Centre, and is an NIHR Senior Investigator. KAL is supported by the Royal Society and the Wellcome Trust (107652/Z/15/Z). The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, Department of Health, or UKHSAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received ethical approval from the South Central Berkshire B Research Ethics Committee (20/SC/0195)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesA privacy preserving version of the lineage dataset is available from https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/covid19infectionsurveytechnicaldata/2021. Full SARS-CoV-2 genome data can be obtained under controlled access from https://www.cogconsortium.uk/data/. Application for full data access requires a description of the planned analysis and can be initiated at coguk_DataAccess{at}medschl.cam.ac.uk.